Jean-Sebastien Frenel, Professor of Medical Oncology at the University of Nantes, shared a post on LinkedIn:
“Very proud to have presented the interim results of the PYNNACLE trial at European Society of Gynaecological Oncology (ESGO)
The PYNNACLE clinical trial is a pivotal Phase 1/2 study evaluating rezatapopt, a small molecule designed to selectively reactivate mutant p53 proteins.
Unlike traditional chemotherapy, rezatapopt works at the molecular level to restore the tumor-suppressor function of p53 that is disabled by the specific TP53 Y220C mutation.
This mutation is identified in approximately 3% of high-grade serous ovarian cancers – a small but highly actionable subgroup .
What have we learned so far?
- In 51 ovarian cancer patients:
- Overall Response Rate (ORR): 46%
- Median Duration of Response: 8 months
- Safety profile: Very favorable, with only Grade 1–2 treatment-related adverse events observed
The trial is ongoing and recruiting worldwide.
I strongly encourage colleagues to test ovarian cancer patients for the TP53 Y220C mutation and refer eligible patients for this study.
The Phase 1 results have just been published in the The New England Journal of Medicine.
Ultra-precision medicine in ovarian cancer is no longer a concept – it is becoming reality”
Title: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
Authors: Ecaterina E. Dumbrava, Geoffrey I. Shapiro, Aparna R. Parikh, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Alison M. Schram
Other articles from ESGO on OncoDaily.